| Home | E-Submission | Sitemap | Contact Us |  
Search
Clin Exp Emerg Med Search

CLOSE

Editorial Policy > For Authors and Reviewers > Editorial Policy



A. Copyright

The copyright of all published materials is owned by the Korean Society of Emergency Medicine. All authors must sign and submit the Transfer of Copyright Agreement when the paper is accepted for publication. The papers will not be published until the copyright transfer is complete.

B. Open Access Policy

CEEM is an open access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided that the original work is properly cited. Thus, when using the tables or figures of CEEM in other journals or books for scholarly and educational purposes, permission from the publisher of CEEM is not necessary. All articles are available on the journal’s website to all users immediately upon publication and at no cost to readers or authors as CEEM is a platinum open access journal.

C. Data Sharing

CEEM encourages data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters. Authors wishing to do so may deposit their data in a publicly accessible repository and include a link to the digital object identifier (DOI) within the text of the manuscript.

CEEM adheres to the data sharing statement policy in ICMJE Recommendations for Clinical Trials (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical- trial-registration.html). Authors may also refer to the editorial, “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” in JKMS vol. 32, no. 7:1051-1053 (https://doi.org/10.3346/jkms.2017.32.7.1051).

D. Archiving Policy

CEEM provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/3081/) and the National Library of Korea (https://www.nl.go.kr).

E. Preprint Policy

A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer-reviewed scholarly journal. CEEM allows authors to submit preprints to the journal. It is not treated as duplicate submission or duplicate publication. CEEM recommends that authors disclose the existence of a preprint with its DOI in the letter to the editor during the submission process. Otherwise, a plagiarism check program may flag the results as containing excessive duplication. A preprint submission will be processed through the same peer review process as a usual submission. If a preprint is accepted for publication, the authors are recommended to update the information on the preprint site with a link to the published article in CEEM, including the DOI at CEEM. It is strongly recommended that authors cite the article in CEEM instead of the preprint in their next submission to journals.

F. Article Sharing

Authors can share their submitted/accepted/publisher version (PDF) for any non-commercial uses.

G. Advertising Policy

Eligibility of the Advertised Products or Services
All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies. We reserve the right to decline or cancel any advertisement at any time. Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety of the Korean government in every respect.

Orders Any individuals or organizations who are interested in advertising their products or services on the journal website are encouraged to contact the Editorial Office. The acceptance of advertisement will be discussed by the Editorial Board and will be ultimately approved by the publisher.

Advertisement Fee The advertisement price for one whole page on PDF copy or banner page is open to negotiations. For banner advertisements on the website, the price is negotiable according to the duration of its exposure on the journal homepage.

Disclaimer Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.

E-Submission
Email Alert
Journal Impact Factor 1.9
SCImago Journal & Country Rank

Publishing timeline

Editorial decision
8 Days

Review time
35 Days

Acceptance to publication
29 Days

* Last 12 months

PubMed Central
pubmed
Scopus
embase
DOAJ
google_scholar
koreamed
ksem
ban_bd_2024_01
ban_heuron_2024
ban_pharmbio
Editorial Office
The Korean Society of Emergency Medicine
101-3104, Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
TEL: +82-31-709-0918   E-mail: office@ceemjournal.org
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © by The Korean Society of Emergency Medicine.                 Developed in M2PI